알테오젠

196170KOSDAQ자연과학 및 공학 연구개발업

54.7 / 100

Reference Date: 2026-07-24

Financial Score25.0 / 40

News Sentiment15.7 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 17.5% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Alteogen is a biotech company leveraging platform technologies like Hybrozyme™, NexP™, and NexMab™ to develop and commercialize biopharmaceuticals, with licensing agreements with global pharma firms such as MSD and AstraZeneca, ensuring sustainable revenue through upfront fees, milestones, and royalties. Its key product ALT-B4 offers subcutaneous injection advantages over IV formulations, while its biosimilar business collaborates with Qilu Pharmaceutical to expand market reach.

Number of Employees

161people

Average Salary

149.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

115.53Industry Average 43.640.0Point

2.6x industry avg (risky)

PBR

—Industry Average 2.523.5Point

ROE

39.85Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

1.02Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~202510.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲58.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲340.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 22.1% (improving, 3yr)

Detailed News Sentiment

40 totalPositive 9Neutral 17Negative 14Average Sentiment Score 62.6

Positive
또 가처분 기각…알테오젠, 특허 리스크 덜었다
알테오젠의 특허 분쟁에서 승소로 인해 키트루다 관련 경쟁 리스크가 해소되어 긍정적 영향 기대.
Neutral
키트루다SC 공방, MSD 1승 추가…헤이그 지방법원 할로자임 가처분...
알테오젠과 MSD 간의 키트루다 피하주사 관련 특허 분쟁에서 MSD의 승소 판결이 나왔으나, 직접적인 영향은 제한적임.
Neutral
코스피, 알파벳 실적 앞두고 경계에 '전강후약'…6,797서 마감
코스피의 마감은 알파벳 실적 발표를 앞두고 경계 심리로 인한 조정으로 설명된다.

Detailed Momentum

52-week position1.0Point

Near 52w low (13%, downtrend)

Current 306,500Won52-week high 559,00052-week low 268,000

1-month return0.0Point

1m -17.50% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral[기재정정]주요사항보고서(무상증자결정)2026-07-20
Neutral주주명부폐쇄기간또는기준일설정2026-07-16
Neutral기타주요경영사항 (유가증권시장 이전상장 추진 잠정 유보)2026-07-16
Neutral주권매매거래정지 (무상증자)2026-07-16
Neutral주요사항보고서(무상증자결정)2026-07-16